Literature DB >> 7508683

Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

R M Tuder1, B Groves, D B Badesch, N F Voelkel.   

Abstract

The plexiform lesion in primary pulmonary hypertension is a glomeruloid structure forming channels in branches of the pulmonary artery. These lesions have been considered an abnormal growth of modified smooth muscle cells. We present immunohistochemical evidence in 10 cases of plexogenic pulmonary hypertension that the plexiform channels and the concentric obliterative arteriopathy associated with these channels represent abnormal growth of factor VIII-related antigen-positive endothelial cells. In addition, these cells strongly expressed vimentin, a growth- and differentiation-related intermediate filament. Morphologically and immunohistochemically, the lesions resembled the neovascularization associated with the brain tumor glioblastoma multiform. Furthermore, we noted an exclusively perivascular inflammatory cell infiltrate (but no vasculitis) in seven of the 10 cases with plexogenic arteriopathy composed of T cells, B cells, and macrophages. Our findings indicate that the plexiform lesion may result from a deregulated growth of endothelial cells. The presence of perivascular inflammatory cells suggested that cytokines and growth factors may further influence the development of the plexiform lesion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508683      PMCID: PMC1887146     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  The histopathology of 36 cases of plexogenic pulmonary arteriopathy.

Authors:  A W Caslin; D Heath; B Madden; M Yacoub; J R Gosney; P Smith
Journal:  Histopathology       Date:  1990-01       Impact factor: 5.087

2.  Electron microscopy of the plexiform lesion.

Authors:  P Smith; D Heath
Journal:  Thorax       Date:  1979-04       Impact factor: 9.139

3.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

4.  Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats.

Authors:  D W Wilson; H J Segall; L C Pan; S K Dunston
Journal:  Microvasc Res       Date:  1989-07       Impact factor: 3.514

5.  Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.

Authors:  H I Palevsky; B L Schloo; G G Pietra; K T Weber; J S Janicki; E Rubin; A P Fishman
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

6.  The ultrastructure of the various forms of pulmonary arterial intimal fibrosis.

Authors:  A G Balk; K P Dingemans; C A Wagenvoort
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-05-31

7.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells.

Authors:  T A Brock; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

8.  Pulmonary hypertension induced by repeated pulmonary inflammation in the rat.

Authors:  J Herget; F Palecek; P Preclík; M Cermáková; M Vízek; M Petrovická
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-09

9.  Granulocyte depletion attenuates sustained pulmonary hypertension and increased pulmonary vasoreactivity caused by continuous air embolization in sheep.

Authors:  E A Perkett; K L Brigham; B Meyrick
Journal:  Am Rev Respir Dis       Date:  1990-02

10.  Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension.

Authors:  M N Gillespie; S E Goldblum; D A Cohen; C J McClain
Journal:  Proc Soc Exp Biol Med       Date:  1988-01
View more
  268 in total

1.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.

Authors:  C D Cool; J S Stewart; P Werahera; G J Miller; R L Williams; N F Voelkel; R M Tuder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion.

Authors:  R M Tuder; N F Voelkel
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 3.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 4.  New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Authors:  N Rudarakanchana; R C Trembath; N W Morrell
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

5.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 6.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

7.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

Review 8.  The immune system in hypertension.

Authors:  Daniel W Trott; David G Harrison
Journal:  Adv Physiol Educ       Date:  2014-03       Impact factor: 2.288

9.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

10.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.